Bluechiip Ltd (ASX:BCT) provides Open Briefing interview with MD Andrew McLellan.
Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.
The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Further information is available at http://www.bluechiip.com
Bluechiip Limited (ASX:BCT) today released its quarterly cash flow report for the period ended 30 September 2018.
Bluechiip Limited (ASX:BCT), a leader in the development of sample-tracking technology for harsh environments, is pleased to report the Share Purchase Plan announced on 10 September 2018, closed on Friday 28 September 2018 and raised approximately $1.95 million.
Bluechiip Ltd (ASX:BCT) provides the Company's Annual Report to shareholders.
Bluechiip Limited (ASX:BCT), is pleased to confirm that, further to the ASX Release dated 10 September 2018, the Company has completed the share placement (Placement) of ordinary shares that has raised $5.5 million of funding.
Bluechiip Limited (ASX:BCT), a leader in the development of sample-tracking technology for harsh environments, today announced it has successfully raised $5.5 million via an oversubscribed placement to sophisticated and professional investors.
Bluechiip Ltd (ASX:BCT) provides the record of Open Briefing interview with MD Andrew McLellan.
Bluechiip Limited (ASX:BCT) a leader in the development of sample-tracking technology for harsh environments, today announced the signing of a three-year $US11.6 million ($A15.9 million) deal to supply its chips and associated hardware and services to vial manufacturer Labcon North America.
Bluechiip Ltd (ASX:BCT) provides the Company's 2017-18 Highlights.
Bluechiip Limited (ASX:BCT) today released its quarterly cash flow report for the period ended 30 June 2018.